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Condensation  
Low selenium status in UK pregnant women is significantly associated with a greater risk of 
occurrence of preeclampsia and more severe expression of the disease.    
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Low selenium status is associated with the occurrence of the pregnancy 
disease preeclampsia in UK women 
Margaret P. Rayman, Peter Bode, Christopher W. G. Redman  
 
OBJECTIVE:  As the trace element selenium behaves as an antioxidant and peroxynitrite 
scavenger when incorporated into selenoproteins, our objective was to determine whether low 
selenium status was associated with a greater risk of occurrence of preeclampsia.  
STUDY DESIGN:  53 preeclamptic patients and 53 matched pregnant controls at the John 
Radcliffe Hospital, Oxford, gave clippings of their toenails (laid down from 3-12 months 
previously) for selenium determination by neutron activation analysis.  Clinical characteristics of 
the women and their infants were recorded.  Statistical analysis was by Wilcoxon’s signed rank 
test and odds ratios were calculated by the ratio of discordant pairs. 
RESULTS:  Median toenail selenium concentrations in the preeclamptic subjects were 
significantly lower than in their matched controls (P=0.001).  Being in the bottom tertile of 
toenail selenium was associated with a 4.4-fold (95% CI 1.6-14.9) greater incidence of the 
condition.  Within the preeclamptic group, lower selenium status was significantly associated 
(P=0.029) with more severe expression of disease, as measured by delivery before 32 weeks.  
CONCLUSION:  In the light of the reduction in selenium status in a number of European 
countries in recent years, this study raises the question of whether a small increase in selenium 
intake might help prevent preeclampsia in susceptible women. 
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Preeclampsia is a major complication of pregnancy that is associated with high maternal and 
perinatal morbidity and mortality.   It is one of the major indications for elective premature 
delivery as there is currently no other cure.  
Poor placentation is an early preclinical development, the consequences of which are 
placental ischaemia and oxidative stress.1  Blood-borne agents arising from the ischaemic 
placenta are believed to cause a maternal systemic inflammatory response that includes 
generalized endothelial-cell dysfunction, which gives rise to the characteristic symptoms of 
hypertension, proteinuria and sudden oedema.2,3  These blood-borne agents, though undefined, 
are thought likely to be products of placental oxidative stress.3  In support of this theory, markers 
of oxidative-stress have been identified both in the preeclamptic placenta and the maternal 
circulation4, while in a controlled trial, antioxidant supplements (vitamins C and E) were found 
to reduce the incidence of pre-eclampsia in women at high risk of developing the condition.5  
The powerful oxidizing and nitrating agent peroxynitrite is a candidate mediator of the 
endothelial dysfunction of preeclampsia.6  There is evidence that peroxynitrite is formed in both 
the placental and systemic vasculature of women with preeclampsia to a significantly greater 
extent than in normal pregnancy.6-8  The endothelium being a constant source of nitric oxide is a 
predominant site of peroxynitrite generation when cells generating superoxide are in the 
vicinity.9  Peroxynitrite is a potent inflammatory mediator10, causes vasoconstriction, platelet 
aggregation and thrombus formation11 and is capable of interacting with signal transduction 
pathways linked to vasoactive agents.12  It therefore has the capacity, directly or indirectly, to 
invoke all the pathological changes observed in the vasculature that culminate in endothelial-cell 
dysfunction.11 
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The trace element selenium, in the context of the antioxidant selenoproteins, is capable of 
limiting adverse endothelial effects.  This is because it removes the products of attack by reactive 
oxygen species (hydroperoxides and oxidized lipoproteins) that can break down to further 
reactive free radicals and cytotoxic agents13 and because selenoprotein P appears to have a 
unique capacity to scavenge peroxynitrite at the endothelial surface.10  We therefore set out to 
explore the possible association between selenium status and the occurrence of pre-eclampsia.   
To overcome the difficulty experienced in a previous study of the disease process 
influencing tissue concentrations of selenium14, we decided to measure selenium status by using 
toenail clippings of preeclamptic women and matched pregnant controls.  This gives a means of 
determining selenium concentration before the development of symptoms and even before 
pregnancy, as toenails are laid down from 3-12 months prior to clipping.15 
In the current study, toenail selenium was determined by neutron activation analysis, the 
usual method for such analyses.  There is a considerable history of the successful use of toenail 
selenium concentration as a biomarker of selenium status.15-17 
 
Material and methods 
Patients.  Fifty-three obstetric patients at the John Radcliffe Hospital, Oxford, were 
identified as suffering from preeclampsia according to the following criteria:- new hypertension, 
from below to consistently at or above 90 mm Hg diastolic pressure; and new proteinuria ≥ 75 
mg/mmol creatinine, in the proven absence of urinary-tract infection.  Patients included in the 
group were generally those showing symptoms of preeclampsia at a relatively early gestational 
age.  In Oxford, women who present with preeclampsia after 36 weeks are delivered promptly so 
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that there is less time to gain informed consent.  Clippings from all ten toenails, free of nail 
varnish, were collected. 
The following clinical characteristics of the patients were recorded:- age, gestational age 
at time of sampling, systolic and diastolic blood pressure, proteinuria, platelet count, aspartate 
aminotransferase (AST) activity (an indicator of liver damage), gestational age at the time of 
delivery, infant sex and birthweight.  Infant birthweights were allocated to centiles using 
“Oxford Standards” charts (Castlemead, Ware UK) allowing correction for length of gestation 
and sex. 
A matched control was selected for each preeclamptic patient from the ante-natal clinic 
according to the following criteria:- same age ± 4 years; same gestation ± 13 days; same parity 
group namely 0, 1-3 or 4 or above.  Matching for other risk factors was not attempted. Controls 
had all conceived spontaneously, had never have received a blood transfusion and were not on 
any medication.  Patients and controls were asked if they took any vitamin or mineral 
supplements, smoked or were vegetarian.  The clinical characteristics of the subjects, who were 
recruited between 1996 and 2001, are recorded in Table 1.   
The Central Oxford Research Ethics Committee approved the study.  
Toenail preparation and analysis.  Toenails were prepared for analysis according to the 
protocol developed for hair analysis by the International Atomic Energy Agency.18  The toenail 
samples were placed in acid-washed beakers and washed sequentially with acetone (1 min), 
distilled deionized water (three washes of 3 min) and acetone (1 min) in a sonic bath.  If nail 
varnish was visibly present, the initial acetone wash was continued for a longer time.  The 
samples were placed in a drying oven for two hours at 500C, that being the length of time 
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required to achieve a constant weight.  The dried samples, of typical mass 12 to 135 mg, were 
then weighed into polyethylene capsules ready for analysis.  
The selenium content was determined by instrumental neutron activation analysis, using 
the facilities of the Interfaculty Reactor Institute in Delft.  The samples were irradiated for a 
period of 4 h in a thermal neutron flux of approximately 5*1016 m-2s-1 together with neutron flux 
monitors and quality control samples.  The radioactivity of the radionuclide 75Se was measured 
via gamma-ray spectroscopy using a well-type Ge-detector.  The counting was carried out 
approximately 20 days after irradiation over a period of 1 h.  Quantification was based on the 
single comparator method.  The quality control samples included a blank capsule and a sample of 
a certified reference material, viz. NIST SRM 1577b Bovine Liver.  The selenium concentration, 
corrected for the contribution of the blank, was determined together with the combined 
measurement uncertainty covering the most important contributions.   
Analysis of NIST SRM 1577b Bovine Liver gave a mean and combined standard 
uncertainty (45 determinations) of 0.73±0.005 mgkg-1, compared to a certified mean and 
standard deviation of 0.74±0.02 mgkg-1demonstrating excellent accuracy of the method. The 
laboratory has an embedded quality control system for quality assurance and management, which 
complies with the requirements of the International Standard ISO/IEC 17025:1999 and has been 
accredited by the Dutch Council for Accreditation since 1993. 
Statistical analysis.  Since toenail selenium concentrations in the preeclamptic and 
control matched pairs were positively skewed, they were compared by Wilcoxon’s Signed Rank 
Test for non-parametric, paired data.  
Cases and controls were ranked in tertiles on the basis of toenail selenium.  The odds 
ratio of having preeclampsia for women in the lowest selenium tertile compared to the rest, and 
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for women in the top tertile compared to the rest, were calculated by the ratio of discordant pairs.  
95% confidence intervals were calculated by the method of Breslow and Day. 
Early delivery19 (<32 weeks) and birthweight less than the third centile were selected as 
indices to test if more severe disease correlated with selenium status.  Preeclamptic subjects were 
divided into tertiles on the basis of toenail selenium.  The χ2 test, or Fisher's Exact Test where 
cell numbers were <5, were used to see if there was a significant difference between tertiles with 
respect to numbers of babies delivered earlier than 32 weeks or birthweight <3rd centile.  
To determine whether selenium was significantly lower in those born before 32 weeks, 
the pre-eclamptic subjects were divided into two groups according to gestational age at birth (> 
or <32 weeks) and a one-tailed Mann-Whitney U test was applied. 
Fisher's Exact test was used to assess whether vegetarianism or the taking of supplements 
in pregnancy affected selenium concentration.  
 
Results 
The clinical characteristics of the two patient groups are shown in Table I.  The 
preeclamptic women were all suffering from moderately-severe to very-severe disease.  Eight 
had AST levels >40 IU/l suggesting a component of liver damage while two had a low platelet 
count (< 100x109 cells/l), also indicative of disease severity.  Two of the pregnancies were 
complicated by the HELLP (hemolysis, elevated liver enzymes, low platelets) or ELLP (elevated 
liver enzymes, low platelets) syndromes.  There were six cases of epigastric pain, a symptom of 
HELLP syndrome.  Infants of three women had perinatal, neonatal or postnatal deaths.  The 
control pregnant women gave birth without developing hypertension or proteinuria, to infants 
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weighing more than 2500g, delivered at 37 weeks or later. All control neonates survived 
normally.  All pregnancies were singleton pregnancies. 
 A scatter-plot of the toenail selenium data from the two groups is shown in Figure 1. 
There was one clear outlier in the control group.  The reason for this is unknown: the subject was 
not on any supplements.  The median of toenail selenium concentrations in the preeclamptic 
women was significantly lower at 0.56 mg/kg (interquartile range 0.51-0.64), than in the control 
women at 0.62 mg/kg (interquartile range 0.57-0.69; P<0.001).  When all 106 women were 
ranked in tertiles according to toenail selenium (Table II), it was apparent that almost half the 
preeclamptic subjects, but only around one eighth of the controls, fell into the bottom tertile.  For 
both groups, the remaining subjects were equally distributed between the middle and top tertiles.  
This suggests a threshold effect of toenail selenium on risk, with the greatest risk of preeclampsia 
being associated with the lowest selenium tertile.  Odds ratios, calculated so as to take the 
matched pairing into account, are shown in Table III.  The odds of having preeclampsia if in the 
lowest tertile rather than the middle or upper, are markedly higher, at 4.4:1.  The bounds of the 
95% confidence interval (CI, 1.6-14.9) indicate that this is a significant finding.  
Further analyses were confined to the preeclampsia group to determine if the severity of 
the disease correlated with selenium status.  The preeclamptic subjects were ranked in tertiles 
according to toenail selenium.  There was no significant difference between the tertiles in terms 
of the number of babies whose birthweight was less than the third centile.  However there were 
significantly fewer women (one only) in the top tertile who delivered at less than 32 weeks 
(P<0.0001). 
When the preeclamptic subjects were divided into two groups according whether they 
delivered their babies before or after 32 weeks gestation, the 11 women with babies delivered 
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before 32 weeks (a measure of disease severity19) had a significantly lower selenium status than 
the 42 women who delivered after 32 weeks (median and range, 0.51, 0.35-0.45 mg/kg vs. 0.56, 
0.36-0.79 mg/kg respectively, P=0.029).  
The main dietary sources of selenium in the UK are meat, poultry and fish13 therefore 
vegetarians are likely to have a lower intake of selenium.  There were only four vegetarians in 
the pre-eclampsia group and their selenium status was not different from the rest.  Neither did the 
taking of supplements during pregnancy affect selenium status. Too few women in either group 
smoked (two in the control group and four in the preeclamptic group) to analyze the data with 
respect to smoking prevalence. 
 
Comment 
The results of this case-control study have shown that for UK pregnant women, being in 
the bottom tertile of selenium status in the period spanning 3-12 months prior to the development 
of preeclampsia is associated with a 4.4-fold greater incidence of the condition.  
Moreover those preeclamptic women with the lowest selenium status had the most severe 
disease in terms of the earliest onset, but not in terms of having babies with the lowest 
birthweight centile.  Our findings are consistent with the results of a small supplementation trial 
carried out in China in women in late pregnancy where 100 µg selenium/day was shown to 
prevent pregnancy-induced hypertension and gestational edema in women deemed to be at risk 
of pregnancy-induced hypertension.20   
Since selenium enters the food chain through plants, soil concentration, geochemistry and 
rainfall largely determine selenium status, which varies considerably throughout the world.13   
Thus toenail selenium concentrations in this study are similar to those measured in women in the 
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Netherlands [0.575±0.109 mg/kg (mean±SD)]16 but considerably lower than those in US women 
[0.83±0.16 - 0.92±0.15 mg/kg (mean±SD)].17  The relatively low selenium status observed in 
this group is consistent with our previous finding of low selenium status in normal obstetric 
patients, of average gestation 33 weeks, attending the same hospital (median plasma selenium 
48.5 µg/l, range 23.1-101.4)21 and the lower selenium status found in most parts of Europe when 
compared to North America.13  A repeat of our study in an area of higher selenium status (e.g. 
the US where dietary intakes of selenium are higher13) might not show an association between 
selenium status and risk of developing preeclampsia.  
In our study, the mean toenail selenium among women who smoked (four preeclamptic 
women and two controls) was lower than the mean in the non-smokers (0.512 vs. 0.597 mg/kg) 
in accordance with previous findings.16  
 There are a number of ways in which selenium in selenoproteins could reduce the risk 
and severity of preeclampsia.  Antioxidant selenoproteins can protect the endothelium by down-
regulating cytokine-induced adhesion-molecule expression and reducing inflammation.22  The 
family of glutathione peroxidases (GPxs) reduces hydrogen peroxide, lipid and phospholipid 
hydroperoxides, even when integrated into lipoproteins or membranes.13  This prevents their 
breakdown into further reactive oxygen species and cytotoxic aldehydes, reducing the risk of 
damage to the endothelium.13  Lipid hydroperoxides are also produced by the lipoxygenase and 
cyclooxygenase pathways leading to prostaglandins, leukotrienes and lipoxins.13  GPxs 
metabolise these lipid hydroperoxides, modulating the production of inflammatory and pro-
aggregatory products e.g. hydroperoxide removal maintains the production of the anti-
aggregatory prostacyclin while decreasing the production of the pro-aggregatory thromboxane.13  
(The balance of these two eicosanoids favours blood-clotting in preeclampsia.21)  Overall, the 
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effect of the GPxs is to reduce the activity of the cyclooxygenases and lipoxygenases which 
require a minimum peroxide tone to be optimally active, thus they limit the production of 
inflammatory and pro-agreggatory prostaglandins and leukotrienes.13  Furthermore GPx rapidly 
reduces peroxynitrite to harmless products.10,11  GPx activity was found to be significantly lower 
in preeclamptic than in normal placental tissue.23  
Another selenoprotein, thioredoxin reductase (TR), can reduce and detoxify hydrogen 
peroxide and some lipid peroxides more efficiently than GPxs.24  Pre-incubation of an 
endothelial cell line with physiologically relevant concentrations of selenium protected the cells 
from oxidative damage by organic peroxides and oxidised LDL through the induction of TR and 
GPxs.24  TR can also reduce dehydroascorbic acid and the ascorbyl free radical back to 
ascorbate.25  Recycling of ascorbate from its oxidized forms is essential to maintain in vivo 
ascorbate levels25 that help to contain oxidative damage to endothelial cells which contain, on a 
molar basis, more TR than GPxs.24 
Selenoprotein P may have a special role in the defense of human plasma against 
peroxynitrite.26  It binds to endothelial cells through heparin-binding domains that enable it to 
coat the surface of cellular membranes, attaching more strongly in the acidotic conditions 
associated with areas of inflammation.27   Its localization to endothelial cells appears to be 
relevant to its anti-oxidant function which has been demonstrated in the in vitro protection of 
human plasma from oxidation and nitration mediated by peroxynitrite26 and in the protection of 
the liver from oxidant injury.27  Whether a significant antioxidant role for selenoprotein P in 
preeclampsia is possible depends on the provision of reducing equivalents in the plasma to 
regenerate the reduced form of selenoprotein P26, thereby maintaining a catalytic process.  
However, because selenoprotein P binds to cell membranes, high local concentrations of the 
  
13
protein27, together with the continuous slow release from cells of the reductant glutathione, may 
represent a significant source of enzymatic activity.28   
Selenoprotein P concentrations in plasma are known to be a useful marker of selenium 
status though neither circulating nor tissue concentrations of selenoprotein P have been measured 
in human pregnancy.  In a UK study, selenoprotein P and plasma GPx together were found to 
account for up to 90% of total plasma selenium (cited in reference 26).  The greater importance 
of selenoprotein P, however, is indicated by the fact that its concentration was preserved relative 
to that of plasma GPx (GPx-3) in subjects reducing their selenium intake.29  Relatively low 
selenium status prior to pregnancy (as measured by toenail selenium concentration) may 
adversely affect the functional activity of the selenoproteins, reducing their protective effect 
against oxidative stress.  This situation may be exacerbated by the expansion in plasma volume 
and reduced plasma selenium concentration normally associated with pregnancy.21   
Implications.  Given the serious nature of preeclampsia and the potentially adverse 
consequences of premature delivery and the associated low birthweight, our results may have 
important public-health implications, particularly in the light of the reduction in selenium intake 
and status, both in the UK and in a number of other European countries, over the last 20 to 25 
years.13  Plasma selenium concentrations are now below the optimum for plasma GPx activity, 
generally taken to indicate selenium repletion, in a considerable number of European locations.13  
This study raises the question of whether a small increase in selenium intake might help 
prevent preeclampsia in susceptible women.  We plan to test the hypothesis that adequate 
selenium status is important for antioxidant defense and peroxynitrite scavenging in pregnant 
women at risk of preeclampsia, by carrying out a randomized controlled trial of low-dose 
selenium supplements during pregnancy. 
  
14
ACKNOWLEDGEMENTS 
Our thanks are due to research midwives Beth Truelove, Carol Simms and Hazel Coburn of the 
John Radcliffe Hospital, who assiduously collected the toenail samples over a period of four 
years, to Jill Adair who prepared the toenail samples for analysis, to Mehmet Sarilar of the 
Interfaculty Reactor Unit, TU Delft, who carried out the neutron activation analyses, to John 
Rayman who carried out the data analysis and to Peter Williams for statistical advice. 
 
 
  
15
REFERENCES 
1. Redman CWG, Sargent IL. Placental debris, oxidative stress and pre-eclampsia. Placenta 
2000;21:597-602.  
2.  Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, and McLaughlin MK. Pre-
eclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-1204. 
3.  Redman CWG, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory 
response to pregnancy.  Am J Obstet Gynecol 1999;180:499-506. 
4. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med 
1999;222:222-235. 
5. Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt B, et al. Effect of antioxidants on 
the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 
1999;354:810-816. 
6. Myatt L, Rosenfield RB, Eis AL, Brockman DE, Greer I, Lyall F. Nitrotyrosine residues in 
placenta. Evidence for peroxynitrite formation and action. Hypertension 1996;28:488-93.  
7. Kossejans W, Eis A, Sahay R, Brockman D, Myatt L.  Role of peroxynitrite in altered fetal-
placental vascular reactivity in diabetes or preeclampsia. Am J Physiol Heart Circ Physiol 
2000;278:H1311-1319.  
8. Roggensack AM, Zhang Y, Davidge ST. Evidence for peroxynitrite formation in the 
vasculature of women with preeclampsia. Hypertension 1999; 33: 83-89. 
9. Kooy NW, Royall JA. Agonist-induced peroxynitrite production from endothelial cells.  
 Arch Biochem Biophys 1994;310:352-359. 
10. Arteel GE, Briviba K, Sies H. Protection against peroxynitrite. FEBS Lett 1999;445: 226-
230. 
  
16
11. Lowe D. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide-Biol 
Chem 2000;4:441-458. 
12. Wolin MS. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb 
Vasc Biol 2000;20:1430-42.  
13. Rayman MP. The importance of selenium to human health. Lancet 2000;356:233-241. 
14. Rayman MP, Abou-Shakra FR, Redman CWG, Ward NI. Serum elemental concentrations in 
the pregnancy disease pre-eclampsia. In: Fischer PWF, L’Abbe M, Cockell KA, Gibson RS, 
editors. Proceedings of the 9th International Symposium on Trace Elements in Man and 
Animals. Ottawa, Canada: N. R. C. Research Press; 1997. p. 71-73. 
15. Longnecker MP, Stampfer MJ, Morris JS, Spate V, Baskett C, Mason M, et al. A 1-year trial 
of the effect of high selenium bread on selenium concentrations in blood and toenails.  Am J 
Clin Nutr 1993; 57:408-413. 
16. van den Brandt PA, Goldbohm RA, van't Veer P, Bode P, Hermus RJ, Sturmans F. Predictors 
of toenail selenium levels in men and women. Cancer Epidemiol Biomarkers Prev 
1993;2:107-112.  
17. Garland M, Morris JS, Rosner BA Stampfer MJ, Spate VL, Baskett CJ, et al. Toenail trace 
element levels as biomarkers: reproducibility over a 6-year period.  Cancer Epidemiol 
Biomarkers Prev 1993;2:493-497.  
18. Activation analysis of hair as an indicator of contamination of man by environmental trace 
element pollutants. International Atomic Energy Agency, Report IAEA/RL/50. Vienna: 
International Atomic Energy Agency; 1978.  
19. Redman CWG. Hypertension in pregnancy. In de Swiet M, editor.  Medical Disorders of 
Pregnancy, 4th ed. London: Blackwell Scientific Publications; 2002.  
  
17
20. Han L, Zhou S. Selenium supplement in the prevention of pregnancy induced hypertension. 
Chinese Med J 1994;107:870-871. 
21. Rayman MP, Abou-Shakra FR, Ward NI, Redman CWG. Comparison of selenium levels in 
pre-eclamptic and normal pregnancies. Biol Trace Element Res 1996;55:9-20. 
22. McKenzie RC, Rafferty TS. Effects of selenium on immunity and ageing. In Hatfield DL, 
editor. Selenium: Its Molecular Biology and Role in Human Health. Dordrecht, The 
Netherlands: Kluwer Academic Publishers; 2001. Chapter 21. 
23. Walsh SW, Wang Y. Deficient glutathione peroxidase activity in preeclampsia is associated 
with increased placental production of thromboxane and lipid peroxides. Am J Obstet 
Gynecol 1993;169:1456-1461.  
24. Lewin MH, Arthur JR, Riemersma RA, Nicol F, Walker SW, Millar EM, Howie AF, Beckett 
GJ. Selenium supplementation acting through the induction of thioredoxin reductase and 
glutathione peroxidase protects the human endothelial cell line EAhy926 from damage by 
lipid hydroperoxides.  Biochim Biophys Acta 2002; 1593:85-92. 
25. May JM, Mendiratta S, Hill KE, Burk RF. Reduction of dehydroascorbate to ascorbate by the 
selenoenzyme thioredoxin reductase. J Biol Chem 1997;272:22607-22610. 
26. Arteel GE, Mostert V, Oubrahim H, Briviba K, Abel J, Sies H. Protection by selenoprotein P 
in human plasma against peroxynitrite-mediated oxidation and nitration. Biol Chem 
1998;379:1201-1205. 
27. Burk RF, Hill KE, Boeglin ME, Ebner FF, Chittum HS. Selenoprotein P associates with 
endothelial cells in rat tissues. Histochem Cell Biol 1997;108:11-15. 
28. Saito Y, Hayashi T, Tanaka A, Watanabe Y, Suzuki M. Selenoprotein P in human plasma as 
an extracellular phospholipid glutathione peroxidase. J Biol Chem. 1999;274:2866-2871.  
  
18
29. Persson-Moschos M, Huang W, Srikumar TS, Åkesson B. Selenoprotein P in serum as a 
biochemical marker of selenium status. Analyst. 1995;120:833-836. 
 
 
  
19
FIGURE LEGEND 
 
Fig.  Distribution of toenail selenium concentrations in pre-eclamptic and control subjects.  
Horizontal bars represent median values. 
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Table I. Clinical characteristics of patient groups 
 
 
Parameter  
Control 
mean ± SD 
n = 53  
Preeclampsia 
mean ± SD 
n = 53 
Difference 
P value for 
significance 
Maternal age (years) 30.9 ± 4.6 31.0 ± 4.9 NS 
Zero parity, n (%) 39 (74)*  38 (72)*  NS 
Systolic blood pressure at sampling (mm Hg)**  112 ± 10 147 ± 13 <0.0001 
Diastolic blood pressure at sampling (mm Hg)**  67 ± 8 96 ± 9 <0.0001 
Proteinuria (dipstick method) - 2.3+ ± 1.1 - 
Platelet count (109 cells/l) - 228 ± 82 - 
Aspartate aminotransferase (AST) activity (IU/l) - 31 ± 33 - 
Gestational age at sampling (days) 237 ± 24 238 ± 24 NS 
Gestational age at delivery (days) 279 ± 8 241 ± 21 <0.0001 
Median birth centile 50-90th 3-10th <0.001 
Number of infants <3rd centile 0 18 <0.001 
Infant birth weight, uncorrected (g)  3359 ± 457 1975 ± 793 <0.0001 
Placental weight (g) 630 ± 104 507 ± 172 0.003 
Prenatal vitamin/mineral intake, n (%)***  16 (30.2)*  12 (22.6)*  NS 
Vegetarians, n (%) 13 (24.5)*  4 (7.5)*  0.016 
Smokers, n (%) 2 (3.8)*  4 (7.5)*  NS 
P values calculated from paired-sample t test, Mann-Whitney U test, χ2 test or Fisher’s Exact test as appropriate. 
NS, Not significant 
*Number (%) 
**66% of pre-eclamptic subjects received anti-hypertensive medication (methyldopa and/or nifedipine) 
***excluding folic acid and iron 
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Table II. Distribution of subjects in preeclamptic and control groups by tertile of toenail 
selenium 
Group Number of 
subjects 
Low Se 
0.492 mg/kg* 
Med Se 
0.588 mg/kg* 
High Se 
0.707 mg/kg* 
Pre-eclamptics 53 26 13 14 
Controls 53 9 22 22 
*Mean toenail selenium concentration 
  
22
 
Table III. Case-control pair status by low vs. medium/high selenium tertile, and odds ratio (OR) 
and 95% confidence interval (CI) for pre-eclampsia by lowest tertile vs. rest  
 
  Control  
  Low Se tertile* Medium/High Se tertile 
Case Low Se tertile* 4 22 
 Medium/High Se tertile 5 22 
* mean toenail selenium concentration 0.492 mg/kg 
OR (lowest tertile vs. rest) 22/5 = 4.4; 95% C.I  1.6-14.9 
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Optional table  Table IV. Toenail selenium concentrations in women from other studies 
 
 
Country 
 
Number of 
Subjects 
 
Subjects (age) 
Smokers/non-
smokers 
 
Se concentration (mg/kg) 
Mean ± SD         Median 
 
     Reference 
      
UK  53 
53 
Pregnant controls 
Pre-eclamptics 
0.63±0.09 
0.57±0.10 
0.62 
0.56 
This study 
Netherlands 77 
 
 
270 
All subj. (55-70)  
Smokers 
Non-smokers 
All subjects 
0.693±0.159 
0.65 
0.71 
0.721±0.220 
0.679 
- 
- 
0.689 
van Noord et al. Breast Cancer 
Res Treat 
25: 11-19, 1993 
Netherlands 1248 All subjects 
Smokers 
Non-smokers 
0.575±0.109 
0.548±0.101 
0.581±0.109 
- 
- 
- 
van den Brandt et al.  
Cancer Epidemiol Biomarkers 
Prev 2:107-112, 1993 
Netherlands 1248 
 
All subjects 
 
0.575±0.109 
 
- van den Brandt et al. Cancer Res 
53:4860-5, 1993 
Netherlands 1248 All subjects 
Aged 55-69 
0.575±0.109  - van den Brandt et al. Am J 
Epidemiol 140:20-26, 1994 
USA 503 
144 
258 
All subj. (36-61) 
Smokers 
Never smokers 
0.864±0.257 
0.78 
0.85 
0.833  
- 
- 
Garland et al. J Natl Cancer Inst 
87:497-505, 1995 
USA 127 All subj. yr 1982 
All subj. yr 1988 
0.83±0.16 
0.92±0.15 
0.81 
0.89 
Garland et al. Cancer Epidemiol 
Biomarkers  Prev 2:493-7, 1993 
USA 434 All subjects 0.821± 0.174 - Hunter et al. JAMA 264:1128-31, 
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1990  
USA 96 
659 
146 
311 
All subjects 
All subjects 
Smokers 
Never smokers 
0.748± 0.149 
0.801±0.148 
0.746±0.124 
0.817±0.159 
- 
- 
- 
- 
Hunter et al. Am J Epidemiol 
132:114-22, 1990 
 
Table V. (contd) Toenail selenium concentrations in women from other studies 
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